Skip to main content
SpringerLink
Log in

Autoimmune Hepatitis in the Elderly: Diagnosis and Pharmacologic Management

  • Therapy in Practice
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Autoimmune hepatitis (AIH) may present as acute or chronic hepatitis in the elderly. Advanced hepatic fibrosis and cirrhosis are common on first presentation in this population. In this review, we discuss the presentation, approach to diagnosis and management of AIH in the elderly. As polypharmacy is common in the elderly, careful medication use history is essential for detecting drug-induced AIH-like hepatitis. Steroid-sparing or minimizing therapeutic regimens are preferred to treat AIH in the elderly. For the purpose of induction, budesonide or lower dose prednisone in combination with azathioprine (AZA) regimens are preferred over high-dose prednisone monotherapy due to the higher risk of side effects of the later in the elderly. The goal of maintenance therapy should be to achieve full biochemical and histologic remission. Bone density monitoring and interventions to prevent steroid-related bone disease should be implemented throughout the course of the disease. Liver transplantation should be considered in the elderly patient with liver failure or early hepatocellular carcinoma if there are no significant comorbidities or compromise in functional status.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Al-Chalabi T, et al. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol. 2006;45(4):575–83.

    Article  PubMed  Google Scholar 

  2. Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology. 2006;43(3):532–8.

    Article  PubMed  Google Scholar 

  3. Schramm C, et al. Autoimmune hepatitis in the elderly. Am J Gastroenterol. 2001;96(5):1587–91.

    Article  CAS  PubMed  Google Scholar 

  4. Verslype C, et al. Diagnosis and treatment of autoimmune hepatitis at age 65 and older. Aliment Pharmacol Ther. 2005;21(6):695–9.

    Article  CAS  PubMed  Google Scholar 

  5. Czaja AJ. Diverse manifestations and evolving treatments of autoimmune hepatitis. Minerva Gastroenterol Dietol. 2005;51(4):313–33.

    CAS  PubMed  Google Scholar 

  6. Alvarez F, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31(5):929–38.

    Article  CAS  PubMed  Google Scholar 

  7. Burgart LJ, et al. Recent-onset autoimmune hepatitis. Biopsy findings and clinical correlations. Am J Surg Pathol. 1995;19(6):699–708.

    Article  CAS  PubMed  Google Scholar 

  8. Chen J, Eslick GD, Weltman M. Systematic review with meta-analysis: clinical manifestations and management of autoimmune hepatitis in the elderly. Aliment Pharmacol Ther. 2014;39(2):117–24.

    Article  CAS  PubMed  Google Scholar 

  9. Czaja AJ. Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly. Drugs Aging. 2008;25(3):219–39.

    Article  CAS  PubMed  Google Scholar 

  10. Czaja AJ, Freese DK, American Association for the Study of Liver Diseases. Diagnosis and treatment of autoimmune hepatitis. Hepatology. 2002;36(2):479–97.

    Article  PubMed  Google Scholar 

  11. Kessler WR, et al. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol. 2004;2(7):625–31.

    Article  PubMed  Google Scholar 

  12. Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol. 1994;21(5):866–71.

    Article  CAS  PubMed  Google Scholar 

  13. Okano N, et al. Clinicopathological features of acute-onset autoimmune hepatitis. Hepatol Res. 2003;25(3):263–70.

    Article  PubMed  Google Scholar 

  14. Parker DR, Kingham JG. Type I autoimmune hepatitis is primarily a disease of later life. QJM. 1997;90(4):289–96.

    Article  CAS  PubMed  Google Scholar 

  15. Czaja AJ. Progress in the diagnosis and treatment of autoimmune hepatitis. Minerva Med. 2008;99(6):549–68.

    CAS  PubMed  Google Scholar 

  16. Villalta D, et al. High prevalence of celiac disease in autoimmune hepatitis detected by anti-tissue tranglutaminase autoantibodies. J Clin Lab Anal. 2005;19(1):6–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Volta U, et al. Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis. Dig Dis Sci. 1998;43(10):2190–5.

    Article  CAS  PubMed  Google Scholar 

  18. Cranney A, et al. The Canadian Celiac Health Survey. Dig Dis Sci. 2007;52(4):1087–95.

    Article  PubMed  Google Scholar 

  19. Bullamore JR, et al. Effect of age on calcium absorption. Lancet. 1970;2(7672):535–7.

    Article  CAS  PubMed  Google Scholar 

  20. Gallagher JC, et al. Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients: effect of age and dietary calcium. J Clin Invest. 1979;64(3):729–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Rubio-Tapia A, Murray JA. Liver involvement in celiac disease. Minerva Med. 2008;99(6):595–604.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Volta U, et al. Celiac disease in autoimmune cholestatic liver disorders. Am J Gastroenterol. 2002;97(10):2609–13.

    Article  PubMed  Google Scholar 

  23. Al-Chalabi T, et al. Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. J Hepatol. 2008;48(1):140–7.

    Article  CAS  PubMed  Google Scholar 

  24. Kaya M, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol. 2000;33(4):537–42.

    Article  CAS  PubMed  Google Scholar 

  25. Omagari K, et al. Re-analysis of clinical features of 89 patients with autoimmune hepatitis using the revised scoring system proposed by the International Autoimmune Hepatitis Group. Intern Med. 2000;39(12):1008–12.

    Article  CAS  PubMed  Google Scholar 

  26. van Buuren HR, et al. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol. 2000;33(4):543–8.

    Article  PubMed  Google Scholar 

  27. Czaja AJ, Carpenter HA, Manns MP. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology. 1993;105(5):1522–8.

    Article  CAS  PubMed  Google Scholar 

  28. Kenny RP, et al. Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis. Dig Dis Sci. 1986;31(7):705–11.

    Article  CAS  PubMed  Google Scholar 

  29. Mishima S, et al. Clinical implications of antimitochondrial antibodies in type 1 autoimmune hepatitis: a longitudinal study. Hepatogastroenterology. 2008;55(81):221–7.

    CAS  PubMed  Google Scholar 

  30. Montano-Loza AJ, Carpenter HA, Czaja AJ. Frequency, behavior, and prognostic implications of antimitochondrial antibodies in type 1 autoimmune hepatitis. J Clin Gastroenterol. 2008;42(9):1047–53.

    Article  PubMed  Google Scholar 

  31. Nezu S, et al. Presence of antimitochondrial autoantibodies in patients with autoimmune hepatitis. J Gastroenterol Hepatol. 2006;21(9):1448–54.

    CAS  PubMed  Google Scholar 

  32. O’Brien C, et al. Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology. 2008;48(2):550–6.

    Article  PubMed  Google Scholar 

  33. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology. 1998;28(2):360–5.

    Article  CAS  PubMed  Google Scholar 

  34. Bjornsson E, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010;51(6):2040–8.

    Article  PubMed  Google Scholar 

  35. Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011;56(4):958–76.

    Article  CAS  PubMed  Google Scholar 

  36. Fujiwara K, Yokosuka O. Histological discrimination between autoimmune hepatitis and drug-induced liver injury. Hepatology. 2012;55(2):657.

    Article  PubMed  Google Scholar 

  37. Kaymakoglu S. Drug-induced hepatitis, drug-induced autoimmunity or classical autoimmune hepatitis: how can we differentiate? Turk J Gastroenterol. 2004;15(3):123–5.

    PubMed  Google Scholar 

  38. Lucena MI, et al. Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. J Hepatol. 2011;55(4):820–7.

    Article  CAS  PubMed  Google Scholar 

  39. Suzuki A, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology. 2011;54(3):931–9.

    Article  PubMed  Google Scholar 

  40. Sokolove J, et al. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis. 2010;69(9):1612–7.

    Article  CAS  PubMed  Google Scholar 

  41. Mancini S, et al. Infliximab-related hepatitis: discussion of a case and review of the literature. Intern Emerg Med. 2010;5(3):193–200.

    Article  PubMed  Google Scholar 

  42. Chalasani N, Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology. 2010;138(7):2246–59.

    Article  CAS  PubMed  Google Scholar 

  43. Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet. 2005;44(1):33–60.

    Article  CAS  PubMed  Google Scholar 

  44. Hennes EM, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48(1):169–76.

    Article  PubMed  Google Scholar 

  45. Lewis JH, Zimmerman HJ. Drug-induced autoimmune liver disease. In: Krawitt EL, Wiesner R, Nishioka K, editors. Autoimmune liver diseases. Elsevier: Amsterdam; 1998. p. 627–49.

    Google Scholar 

  46. Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis. 2002;6(3):755–74.

    Article  PubMed  Google Scholar 

  47. Andrade RJ, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512–21.

    Article  PubMed  Google Scholar 

  48. Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology. 2006;43(3):618–31.

    Article  PubMed  Google Scholar 

  49. Bjornsson E, Davidsdottir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol. 2009;50(3):511–7.

    Article  PubMed  Google Scholar 

  50. Bjornsson E, et al. Long-term follow-up of patients with mild to moderate drug-induced liver injury. Aliment Pharmacol Ther. 2007;26(1):79–85.

    Article  CAS  PubMed  Google Scholar 

  51. Hegarty JE, et al. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology. 1983;3(5):685–9.

    Article  CAS  PubMed  Google Scholar 

  52. Zauli D, et al. Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. Hepatology. 1997;25(5):1105–7.

    Article  CAS  PubMed  Google Scholar 

  53. Available from: https://livertox.nih.gov/Phenotypes_auto.html.

  54. Czaja AJ, et al. The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology. 1993;104(6):1755–61.

    Article  CAS  PubMed  Google Scholar 

  55. Czaja AJ, et al. Clinical and prognostic implications of HLA B8 in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology. 1990;98(6):1587–93.

    Article  CAS  PubMed  Google Scholar 

  56. Gassert DJ, et al. Corticosteroid-responsive cryptogenic chronic hepatitis: evidence for seronegative autoimmune hepatitis. Dig Dis Sci. 2007;52(9):2433–7.

    Article  CAS  PubMed  Google Scholar 

  57. Potthoff A, et al. Steroid treatment for severe acute cryptogenic hepatitis. Z Gastroenterol. 2007;45(1):15–9.

    Article  CAS  PubMed  Google Scholar 

  58. Provenzano G, Marino L, Craxi A. Features of autoimmunity in cryptogenic chronic hepatitis. Allergol Immunopathol (Madr). 1991;19(3):119–22.

    CAS  Google Scholar 

  59. Rowley MJ, Buchanan H, Mackay IR. Reciprocal change with age in antibody to extrinsic and intrinsic antigens. Lancet. 1968;2(7558):24–6.

    Article  CAS  PubMed  Google Scholar 

  60. Hooper B, et al. Autoimmunity in a rural community. Clin Exp Immunol. 1972;12(1):79–87.

    CAS  PubMed  PubMed Central  Google Scholar 

  61. Talor E, Rose NR. Hypothesis: the aging paradox and autoimmune disease. Autoimmunity. 1991;8(3):245–9.

    Article  CAS  PubMed  Google Scholar 

  62. Currie MS. Immunosenescence. Compr Ther. 1992;18(11):26–34.

    CAS  PubMed  Google Scholar 

  63. Duerr RH, et al. Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology. 1991;100(5 Pt 1):1385–91.

    Article  CAS  PubMed  Google Scholar 

  64. Frenzer A, et al. Atypical, cytoplasmic and perinuclear anti-neutrophil cytoplasmic antibodies in patients with inflammatory bowel disease. J Gastroenterol Hepatol. 1998;13(9):950–4.

    Article  CAS  PubMed  Google Scholar 

  65. LaBrecque D, et al. Antineutrophil cytoplasmic antibody and chronic liver disease. Hepatology. 1999;30:428A.

    Google Scholar 

  66. Targan SR, et al. High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterology. 1995;108(4):1159–66.

    Article  CAS  PubMed  Google Scholar 

  67. Manns MP, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51(6):2193–213.

    Article  CAS  PubMed  Google Scholar 

  68. Wies I, et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet. 2000;355(9214):1510–5.

    Article  CAS  PubMed  Google Scholar 

  69. Baeres M, et al. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut. 2002;51(2):259–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Ma Y, et al. Anti-SLA antibody is a marker of severity of liver damage in patients with autoimmune liver disease. J Hepatol. 2001;34(Suppl 1):1–257.

    Google Scholar 

  71. Torres-Collado AX, Czaja AJ, Gelpi C. Anti-tRNP(ser)sec/SLA/LP autoantibodies. Comparative study using in-house ELISA with a recombinant 48.8 kDa protein, immunoblot, and analysis of immunoprecipitated RNAs. Liver Int. 2005;25(2):410–9.

    Article  CAS  PubMed  Google Scholar 

  72. Vitozzi S, et al. Anti-soluble liver antigen/liver-pancreas (SLA/LP) antibodies in pediatric patients with autoimmune hepatitis. Autoimmunity. 2002;35(8):485–92.

    Article  CAS  PubMed  Google Scholar 

  73. Gatselis NK, et al. Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: a new or a complementary diagnostic score? Dig Liver Dis. 2010;42(11):807–12.

    Article  PubMed  Google Scholar 

  74. Czaja AJ. Comparability of probable and definite autoimmune hepatitis by international diagnostic scoring criteria. Gastroenterology. 2011;140(5):1472–80.

    Article  PubMed  Google Scholar 

  75. Longhi MS, et al. Aetiopathogenesis of autoimmune hepatitis. J Autoimmun. 2010;34(1):7–14.

    Article  CAS  PubMed  Google Scholar 

  76. Baggenstoss AH, et al. Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution. Hum Pathol. 1972;3(2):183–98.

    Article  CAS  PubMed  Google Scholar 

  77. Cooksley WG, et al. The prognosis of chronic active hepatitis without cirrhosis in relation to bridging necrosis. Hepatology. 1986;6(3):345–8.

    Article  CAS  PubMed  Google Scholar 

  78. Schalm SW, et al. Severe chronic active liver disease. Prognostic significance of initial morphologic patterns. Am J Dig Dis. 1977;22(11):973–80.

    Article  CAS  PubMed  Google Scholar 

  79. Czaja AJ. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int. 2009;29(6):816–23.

    Article  CAS  PubMed  Google Scholar 

  80. Koretz RL, et al. Chronic active hepatitis. Who meets treatment criteria? Dig Dis Sci. 1980;25(9):695–9.

    Article  CAS  PubMed  Google Scholar 

  81. Feld JJ, et al. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology. 2005;42(1):53–62.

    Article  PubMed  Google Scholar 

  82. Kogan J, et al. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol. 2002;35(1):75–81.

    Article  PubMed  Google Scholar 

  83. Manns MP, Lohse AW, Vergani D. Autoimmune hepatitis–update 2015. J Hepatol. 2015;62(1 Suppl):S100–11.

    Article  PubMed  Google Scholar 

  84. Sahebjam F, Vierling JM. Autoimmune hepatitis. Front Med. 2015;9(2):187–219.

    Article  PubMed  Google Scholar 

  85. Czaja AJ. Review article: the prevention and reversal of hepatic fibrosis in autoimmune hepatitis. Aliment Pharmacol Ther. 2014;39(4):385–406.

    Article  CAS  PubMed  Google Scholar 

  86. Shah AM, et al. Reversal of liver cirrhosis in autoimmune hepatitis. Hepatogastroenterology. 2011;58(112):2115–7.

    CAS  PubMed  Google Scholar 

  87. Czaja AJ. Treatment strategies in autoimmune hepatitis. Clin Liver Dis. 2002;6(3):799–824.

    Article  PubMed  Google Scholar 

  88. Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology. 1988;95(2):448–53.

    Article  CAS  PubMed  Google Scholar 

  89. Czaja AJ, Ammon HV, Summerskill WH. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. Gastroenterology. 1980;78(3):518–23.

    Article  CAS  PubMed  Google Scholar 

  90. Czaja AJ, Beaver SJ, Shiels MT. Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology. 1987;92(1):215–9.

    Article  CAS  PubMed  Google Scholar 

  91. Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology. 2002;35(4):890–7.

    Article  CAS  PubMed  Google Scholar 

  92. Czaja AJ, Wolf AM, Baggenstoss AH. Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology. 1981;80(4):687–92.

    Article  CAS  PubMed  Google Scholar 

  93. Soloway RD, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology. 1972;63(5):820–33.

    Article  CAS  PubMed  Google Scholar 

  94. Wang KK, Czaja AJ. Prognosis of corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis in postmenopausal women: a retrospective analysis. Gastroenterology. 1989;97(5):1288–93.

    Article  CAS  PubMed  Google Scholar 

  95. Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clin Proc. 2002;77(5):453–68.

    Article  PubMed  Google Scholar 

  96. Kanis JA, et al. The components of excess mortality after hip fracture. Bone. 2003;32(5):468–73.

    Article  CAS  PubMed  Google Scholar 

  97. Haentjens P, et al. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med. 2010;152(6):380–90.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Center JR, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999;353(9156):878–82.

    Article  CAS  PubMed  Google Scholar 

  99. Wang KK, et al. Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Hepatology. 1989;10(1):39–43.

    Article  CAS  PubMed  Google Scholar 

  100. Czaja AJ, Carpenter HA. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig Dis Sci. 2006;51(5):968–75.

    Article  CAS  PubMed  Google Scholar 

  101. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med. 1995;333(15):958–63.

    Article  CAS  PubMed  Google Scholar 

  102. Czaja AJ. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf. 2008;7(3):319–33.

    Article  CAS  PubMed  Google Scholar 

  103. Czaja AJ. Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients. Semin Liver Dis. 2009;29(3):315–30.

    Article  PubMed  Google Scholar 

  104. Yeoman AD, Longhi MS, Heneghan MA. Review article: the modern management of autoimmune hepatitis. Aliment Pharmacol Ther. 2010;31(8):771–87.

    CAS  PubMed  Google Scholar 

  105. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol. 2004;40(4):646–52.

    Article  CAS  PubMed  Google Scholar 

  106. Vierling JM. Autoimmune hepatitis and overlap syndromes: diagnosis and management. Clin Gastroenterol Hepatol. 2015;13(12):2088–108.

    Article  PubMed  Google Scholar 

  107. Lamers MM, et al. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol. 2010;53(1):191–8.

    Article  CAS  PubMed  Google Scholar 

  108. Strassburg CP. Therapeutic options to treat autoimmune hepatitis in 2009. Dig Dis. 2010;28(1):93–8.

    Article  PubMed  CAS  Google Scholar 

  109. Manns MP, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010;139(4):1198–206.

    Article  CAS  PubMed  Google Scholar 

  110. Csepregi A, et al. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol. 2006;12(9):1362–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology. 2000;119(5):1312–6.

    Article  CAS  PubMed  Google Scholar 

  112. Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther. 1994;8(6):585–90.

    Article  CAS  PubMed  Google Scholar 

  113. Delgado JS, et al. Autoimmune hepatitis in southern Israel: a 15-year multicenter study. J Dig Dis. 2013;14(11):611–8.

    CAS  PubMed  Google Scholar 

  114. Peiseler, M, et al. Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis. Clin Gastroenterol Hepatol. 2018;16(2):260–67 e1.

    Article  PubMed  CAS  Google Scholar 

  115. Wiegand J, et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int. 2005;25(5):927–34.

    Article  CAS  PubMed  Google Scholar 

  116. Lohse AW, Gil H. Reactivation of autoimmune hepatitis during budesonide monotherapy, and response to standard treatment. J Hepatol. 2011;54(4):837–9.

    Article  PubMed  Google Scholar 

  117. Geier A, et al. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J Gastroenterol. 2003;9(12):2681–5.

    Article  PubMed  PubMed Central  Google Scholar 

  118. Peiseler M, et al. Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis. Clin Gastroenterol Hepatol. 2018;16(2):260–7.

    Article  CAS  PubMed  Google Scholar 

  119. Hindorf U, et al. Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis. J Hepatol. 2010;52(1):106–11.

    Article  CAS  PubMed  Google Scholar 

  120. de Boer YS, et al. Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis. Aliment Pharmacol Ther. 2013;37(6):640–6.

    Article  PubMed  CAS  Google Scholar 

  121. Baven-Pronk AM, et al. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Ther. 2011;34(3):335–43.

    Article  CAS  PubMed  Google Scholar 

  122. Chatur N, et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int. 2005;25(4):723–7.

    Article  CAS  PubMed  Google Scholar 

  123. Inductivo-Yu I, et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol. 2007;5(7):799–802.

    Article  CAS  PubMed  Google Scholar 

  124. Sharzehi K, et al. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can J Gastroenterol. 2010;24(10):588–92.

    Article  PubMed  PubMed Central  Google Scholar 

  125. Roberts SK, et al. Efficacy and safety of mycophenolate mofetil in patients with autoimmune hepatitis and suboptimal outcomes after standard therapy. Clin Gastroenterol Hepatol. 2018;16(2):268–77.

    Article  CAS  PubMed  Google Scholar 

  126. Efe C, et al. Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis. Clin Gastroenterol Hepatol. 2017;15(12):1950–6.

    Article  CAS  PubMed  Google Scholar 

  127. Ilyas JA, O’Mahony CA, Vierling JM. Liver transplantation in autoimmune liver diseases. Best Pract Res Clin Gastroenterol. 2011;25(6):765–82.

    Article  PubMed  Google Scholar 

  128. Schramm C, et al. Primary liver transplantation for autoimmune hepatitis: a comparative analysis of the European Liver Transplant Registry. Liver Transpl. 2010;16(4):461–9.

    PubMed  Google Scholar 

  129. Tanaka T, Sugawara Y, Kokudo N. Liver transplantation and autoimmune hepatitis. Intractable Rare Dis Res. 2015;4(1):33–8.

    Article  PubMed  PubMed Central  Google Scholar 

  130. Seaberg EC, et al. Liver transplantation in the United States from 1987–1998: updated results from the Pitt-UNOS Liver Transplant Registry. Clin Transpl. 1998:17–37.

Download references

Author information

Authors and Affiliations

  1. Gastroenterology and Hepatology Division, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI, 53226, USA

    Syed Rizvi

  2. Gastroenterology and Hepatology Division, Indiana University School of Medicine, 702 Rotary Cir, Indianapolis, IN, 46202-5175, USA

    Samer Gawrieh

Authors
  1. Syed Rizvi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samer Gawrieh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Syed Rizvi or Samer Gawrieh.

Ethics declarations

Funding

Dr. Syed Rizvi and Dr. Samer Gawrieh received no external funding for this study.

Conflict of interest

Dr. Syed Rizvi and Dr. Samer Gawrieh declare no conflicts of interest relevant to this paper.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rizvi, S., Gawrieh, S. Autoimmune Hepatitis in the Elderly: Diagnosis and Pharmacologic Management. Drugs Aging 35, 589–602 (2018). https://doi.org/10.1007/s40266-018-0556-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-018-0556-0

Search

Navigation